Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.32 |
| ▸ | PTGER1 | P34995 | 3/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18993963 | 0.84 | HTR1A (0.33) | CXCR4GRM5TGFBR1PTGER1HRH3 | |
| SCHEMBL21250118 | 0.75 | SCN8A (0.34) | CXCR4TGFBR1 | |
| SCHEMBL26209102 | 0.72 | KCNH2 (0.36) | CXCR4TGFBR1HRH3CYP1A2 | |
| SCHEMBL22639190 | 0.72 | CYP2D6 (0.34) | CXCR4 | |
| SCHEMBL30567627 | 0.70 | CYP11B1 (0.33) | CYP1A2 | |
| SCHEMBL1581851 | 0.70 | KCNH2 (0.36) | CXCR4ADORA2A | |
| SCHEMBL1132718 | 0.70 | LMNA (0.39) | CYP1A2 | |
| SCHEMBL31481285 | 0.70 | KCNH2 (0.36) | CXCR4ADORA2A | |
| SCHEMBL17828026 | 0.69 | ADORA2A (0.43) | CXCR4HRH3ADORA2A | |
| SCHEMBL7358290 | 0.69 | DPP4 (0.33) | CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9782415-B2 | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-20170119770-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2017-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170119770-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | TXK, FRK, LTK | CXCR4 634/4885GRM5 1055/4885TGFBR1 923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.